UBS Group
CTOR

UBS Group’s Citius Oncology CTOR Stock Holding History

UBS Group’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.8K Buy
36,840
+15,376
+72% +$15.4K ﹤0.01% 7836
2025
Q4 		$21.5K Buy
21,464
+21,409
+38,925% +$30.7K ﹤0.01% 7735
2025
Q3 		$112 Sell
55
-15,368
-100% -$33.3K ﹤0.01% 9902
2025
Q2 		$67.1K Sell
15,423
-34,322
-69% -$40.1K ﹤0.01% 7540
2025
Q1 		$46.3K Buy
49,745
+24,940
+101% +$26.7K ﹤0.01% 7651
2024
Q4 		$28.5K Buy
24,805
+23,173
+1,420% +$26K ﹤0.01% 7641
2024
Q3 		$2.27K Buy
+1,632
New +$11.6K ﹤0.01% 8471
2023
Q2 		– Sell
-1,504
Closed -$15.6K – 9791
2023
Q1 		$15.6K Buy
1,504
+1,104
+276% +$11.3K ﹤0.01% 7285
2022
Q4 		$4.06K Buy
+400
New +$4.05K ﹤0.01% 9395

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

UBS Group's CTOR Position: Q1 2026 in Review

UBS Group increased its Citius Oncology (CTOR) stake by 72% in Q1 2026, buying an estimated $15.4K and bringing the position to 36,840 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #7836.

UBS Group first reported a position in CTOR in Q4 2022 and has held it in 9 quarters since. The position peaked at $67.1K in Q2 2025. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

  • UBS Group held 36,840 shares of Citius Oncology worth $22.8K as of Q1 2026.
  • UBS Group bought 15,376 Citius Oncology shares in Q1 2026, an estimated $15.4K.
  • Citius Oncology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7836 holding.
  • UBS Group first reported a position in Citius Oncology in Q4 2022 and has held it in 9 quarters since.
  • UBS Group's Citius Oncology position peaked at $67.1K in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.